MicroPort CardioFlow Medtech Corporation

04 FEB 2021

MicroPort CardioFlow Medtech Corporation (the “Company”) is a medical device company in China focusing on the research, development and commercialization of innovative transcatheter and surgical solutions for valvular heart diseases. The Company’s mission is to improve the lives of valvular heart disease patients by providing optimal and affordable medical solutions through continuous innovation. The Company’s self-developed first-generation transcatheter aortic valve implantation (“TAVI”) product, VitaFlow™, was approved by the NMPA in July 2019 and subsequently commercialized in China in August 2019. According to Frost & Sullivan, VitaFlow™ is the first commercialized TAVI product utilizing bovine pericardium as valve tissue in China.